Tagged with US

USA PhRMA President and CEO Stephen J. Ubl takes aim at the health insurers and pharmacy benefit managers (PBMs) driving medicines costs up in the US, and the Inflation Reduction Act (IRA) which he sees as failing to address the patient affordability conundrum. Ubl calls for a policy framework able to…

China In light of ongoing geopolitical tension, a globally unfavourable macroeconomic environment and new drug-pricing legislation in the US, at the recent BIO CEO and Investor Conference industry stakeholders evaluated the risks and the opportunities for cross-border deal-making between US and China and found a number of reasons to be optimistic.…

Brazil The latest from Brazilian Pharma, including the controversial proposal to transform Brazil’s regulatory agency, ANVISA; Ease Labs’s canabidiol approval, Biolab’s international expansion ambitions and Eurofarma’s multiple myeloma deal.    ANVISA’s autonomy challenged by Congress (Regulatory Focus) After the swearing in Brazilian’s President Luiz Inácio Lula da Silva earlier this year,…

USA With the passage of the US Inflation Reduction Act (IRA) that will begin to take effect this year, the biopharma industry continues to grapple with the implications of the new law while deciding how to move forward in response to it. At the recent BIO CEO and Investor Conference, stakeholders…

Poland Poland’s largest pharmaceutical company and leading generics manufacturer, Polpharma, is looking to expand its presence outside of the country’s borders. With a recent acquisition bid for former Sanofi European generics unit, Zentiva, Polpharma is building on a growing international footprint beyond its CEE base.   Founded over 80 years ago,…

Global IFPMA Director General Thomas Cueni highlights the global innovative pharmaceutical industry’s five key priorities for ensuring better national and international healthcare responses to future pandemics, drawing on the lessons of COVID-19.   The international community is working to rebuild the global health architecture to ensure it is fit for purpose…

Global With the global market for generic drugs expected to reach USD 36.4 billion by 2027 and grow at a CAGR of 5.6 percent over the period 2020-2027, it is not surprising that a number of generics producers continue to rank among the world’s top pharma companies. A look at the…

CEE Some of the most important stories emanating from the Central and Eastern European (CEE) region’s pharma industry, including Polpharma’s bid for Zentiva, Richter’s acquisition of OC Distributors and MDD approval in the US, Hungary’s windfall tax on pharma, Presage’s collaboration with Pure Biologics and Lithuania’s biotech ambitions.   Polpharma working…

USA Global e-commerce giant and the world’s fifth largest company by market capitalisation, Amazon is continuing its expansion into the healthcare space with the launch of a five dollar monthly medicine subscription plan for Amazon Prime members in the US.   The plan, named ‘RxPass’ covers 60 generic medications used to…

Saudi Arabia The latest news from the Saudi healthcare and life science industry, including how the implementation of COVID-19 measures have helped reduce the prevalence of MERS-CoV in the country, regulatory approval for Alvotech and Bioventure’s Humira biosimilar, and Open Medical’s new partnership with Tamer Group around digital transformation solutions.   As…

USA An up-to-date list of the US FDA’s Center for Biologics Evaluation & Research (CBER)’s biological license application approvals for 2022. There were nine such approvals in 2022, down from 13 in 2021. For the list of non-biological approvals from the FDA’s Center for Drug Evaluation & Research (CDER), click here.…

Global For a  biotech that had never before brought a drug to market, Moderna’s COVID-19 vaccine was a revelation. Not only did the vaccine validate the company’s focus on mRNA technology, it also led to huge profits, namely a net income of USD 12.2 billion in 2021 and vaccine sales adding…